This Journal feature begins with a case vignette that includesa therapeutic recommendation. A discussion of the clinical problemand the mechanism of benefit of this form of therapy follows.Major clinical studies, the clinical use of this therapy, andpotential adverse effects are reviewed. Relevant formal guidelines,if they exist, are presented. The article ends with the authors'clinical recommendations.
Rheumatoid arthritis developed in a 25-year-old woman, who wasfound to have a positive rheumatoid factor (150 IU per milliliter);she had no periarticular radiologic erosions or extraarticulardisease. Oral methotrexate was started and incrementally increasedto 20 mg . . . [Full Text of this Article]
The Clinical Problem
Pathophysiology and Effect of Therapy
Clinical Evidence
Clinical Use
Adverse Effects
Areas of Uncertainty
Guidelines
Recommendations
Source Information
From the Department of Rheumatology, Kings College London School of Medicine, Weston Education Centre, Kings College (D.L.S., G.H.K.); the Department of Rheumatology, Kings College Hospital (D.L.S.); and the Department of Rheumatology, University Hospital Lewisham (G.H.K.) all in London.
Hope, H. R., Anderson, G. D., Burnette, B. L., Compton, R. P., Devraj, R. V., Hirsch, J. L., Keith, R. H., Li, X., Mbalaviele, G., Messing, D. M., Saabye, M. J., Schindler, J. F., Selness, S. R., Stillwell, L. I., Webb, E. G., Zhang, J., Monahan, J. B.
(2009). Anti-Inflammatory Properties of a Novel N-Phenyl Pyridinone Inhibitor of p38 Mitogen-Activated Protein Kinase: Preclinical-to-Clinical Translation. J. Pharmacol. Exp. Ther.
331: 882-895
[Abstract][Full Text]
Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., Ghogomu, E. T., Tugwell, P.
(2009). A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ
181: 787-796
[Abstract][Full Text]
Scarpato, S., Antivalle, M., Favalli, E. G., Nacci, F., Frigelli, S., Bartoli, F., Bazzichi, L., Minisola, G., Matucci Cerinic, M., RIVIERA co-authors,
(2009). Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford)
0: kep354v1-kep354
[Abstract][Full Text]
Oflazoglu, E., Boursalian, T. E., Zeng, W., Edwards, A. C., Duniho, S., McEarchern, J. A., Law, C.-L., Gerber, H.-P., Grewal, I. S.
(2009). Blocking of CD27-CD70 Pathway by Anti-CD70 Antibody Ameliorates Joint Disease in Murine Collagen-Induced Arthritis. J. Immunol.
183: 3770-3777
[Abstract][Full Text]
Priori, R, Alessandri, C, Magrini, L, Cassara, E A M, Ceccarelli, F, Modesti, M, Croia, C, Bombardieri, M, Valesini, G
(2009). Nucleosome accumulation and reduction of C-reactive protein are associated with the generation of anti-nuclear antibodies in patients with rheumatoid arthritis treated with adalimumab, but not with etanercept. Ann Rheum Dis
68: 1514-1516
[Full Text]
Yoshizawa, T., Hammaker, D., Boyle, D. L., Corr, M., Flavell, R., Davis, R., Schett, G., Firestein, G. S.
(2009). Role of MAPK Kinase 6 in Arthritis: Distinct Mechanism of Action in Inflammation and Cytokine Expression. J. Immunol.
183: 1360-1367
[Abstract][Full Text]
Vecchione, C., Frati, A., Di Pardo, A., Cifelli, G., Carnevale, D., Gentile, M. T., Carangi, R., Landolfi, A., Carullo, P., Bettarini, U., Antenucci, G., Mascio, G., Busceti, C. L., Notte, A., Maffei, A., Cantore, G. P., Lembo, G.
(2009). Tumor Necrosis Factor-{alpha} Mediates Hemolysis-Induced Vasoconstriction and the Cerebral Vasospasm Evoked by Subarachnoid Hemorrhage. Hypertension
54: 150-156
[Abstract][Full Text]
ODAI, T., MATSUNAWA, M., TAKAHASHI, R., WAKABAYASHI, K., ISOZAKI, T., YAJIMA, N., MIWA, Y., KASAMA, T.
(2009). Correlation of CX3CL1 and CX3CR1 Levels with Response to Infliximab Therapy in Patients with Rheumatoid Arthritis. The Journal of Rheumatology
36: 1158-1165
[Abstract][Full Text]
ROSENAU, B. J., SCHUR, P. H.
(2009). Association of Measles Virus with Rheumatoid Arthritis. The Journal of Rheumatology
36: 893-897
[Abstract][Full Text]
YAZICI, Y., KRASNOKUTSKY, S., BARNES, J. P., HINES, P. L., WANG, J., ROSENBLATT, L.
(2009). Changing Patterns of Tumor Necrosis Factor Inhibitor Use in 9074 Patients with Rheumatoid Arthritis. The Journal of Rheumatology
36: 907-913
[Abstract][Full Text]
Prince, F H M, Twilt, M, Cate, R t., van Rossum, M A J, Armbrust, W, Hoppenreijs, E P A H, van Santen-Hoeufft, M, Koopman-Keemink, Y, Wulffraat, N M, van Suijlekom-Smit, L W A
(2009). Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis
68: 635-641
[Abstract][Full Text]
Horiuchi, K., Kimura, T., Miyamoto, T., Miyamoto, K., Akiyama, H., Takaishi, H., Morioka, H., Nakamura, T., Okada, Y., Blobel, C. P., Toyama, Y.
(2009). Conditional Inactivation of TACE by a Sox9 Promoter Leads to Osteoporosis and Increased Granulopoiesis via Dysregulation of IL-17 and G-CSF. J. Immunol.
182: 2093-2101
[Abstract][Full Text]
Halvorsen, E H, Haavardsholm, E A, Pollmann, S, Boonen, A, van der Heijde, D, Kvien, T K, Molberg, O
(2009). Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-{alpha} blocking agents. Ann Rheum Dis
68: 249-252
[Abstract][Full Text]
Summers, G. D., Deighton, C. M., Rennie, M. J., Booth, A. H.
(2008). Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford)
47: 1124-1131
[Abstract][Full Text]
Pedras-Vasconcelos, J. A., Puig, M., Sauder, C., Wolbert, C., Ovanesov, M., Goucher, D., Verthelyi, D.
(2008). Immunotherapy with CpG Oligonucleotides and Antibodies to TNF-{alpha} Rescues Neonatal Mice from Lethal Arenavirus-Induced Meningoencephalitis. J. Immunol.
180: 8231-8240
[Abstract][Full Text]
Choy, E H S, Smith, C M, Farewell, V, Walker, D, Hassell, A, Chau, L, Scott, D L, for the CARDERA (Combination Anti-Rheumatic Drugs,
(2008). Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis
67: 656-663
[Abstract][Full Text]
Yamashita, M., Otsuka, F., Mukai, T., Otani, H., Inagaki, K., Miyoshi, T., Goto, J., Yamamura, M., Makino, H.
(2008). Simvastatin antagonizes tumor necrosis factor-{alpha} inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol
196: 601-613
[Abstract][Full Text]
Dower, K., Ellis, D. K., Saraf, K., Jelinsky, S. A., Lin, L.-L.
(2008). Innate Immune Responses to TREM-1 Activation: Overlap, Divergence, and Positive and Negative Cross-Talk with Bacterial Lipopolysaccharide. J. Immunol.
180: 3520-3534
[Abstract][Full Text]
Kanamaru, Y., Pfirsch, S., Aloulou, M., Vrtovsnik, F., Essig, M., Loirat, C., Deschenes, G., Guerin-Marchand, C., Blank, U., Monteiro, R. C.
(2008). Inhibitory ITAM Signaling by Fc{alpha}RI-FcR{gamma} Chain Controls Multiple Activating Responses and Prevents Renal Inflammation. J. Immunol.
180: 2669-2678
[Abstract][Full Text]
Zaba, L. C., Cardinale, I., Gilleaudeau, P., Sullivan-Whalen, M., Suarez-Farinas, M., Fuentes-Duculan, J., Novitskaya, I., Khatcherian, A., Bluth, M. J., Lowes, M. A., Krueger, J. G.
(2007). Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. JEM
204: 3183-3194
[Abstract][Full Text]
Araujo, E. P., De Souza, C. T., Ueno, M., Cintra, D. E., Bertolo, M. B., Carvalheira, J. B., Saad, M. J., Velloso, L. A.
(2007). Infliximab Restores Glucose Homeostasis in an Animal Model of Diet-Induced Obesity and Diabetes. Endocrinology
148: 5991-5997
[Abstract][Full Text]
Song, H., Qiao, F., Atkinson, C., Holers, V. M., Tomlinson, S.
(2007). A Complement C3 Inhibitor Specifically Targeted to Sites of Complement Activation Effectively Ameliorates Collagen-Induced Arthritis in DBA/1J Mice. J. Immunol.
179: 7860-7867
[Abstract][Full Text]
Barbuio, R., Milanski, M., Bertolo, M. B, Saad, M. J, Velloso, L. A
(2007). Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol
194: 539-550
[Abstract][Full Text]
Wieser, F., Cohen, M., Gaeddert, A., Yu, J., Burks-Wicks, C., Berga, S. L., Taylor, R. N.
(2007). Evolution of medical treatment for endometriosis: back to the roots?. Hum Reprod Update
13: 487-499
[Abstract][Full Text]
Ma, Y., HayGlass, K. T., Becker, A. B., Fan, Y., Yang, X., Basu, S., Srinivasan, G., Simons, F. E. R., Halayko, A. J., Peng, Z.
(2007). Novel Recombinant Interleukin-13 Peptide-based Vaccine Reduces Airway Allergic Inflammatory Responses in Mice. Am. J. Respir. Crit. Care Med.
176: 439-445
[Abstract][Full Text]
Kitamura, M., Iwabuchi, K., Kitaichi, N., Kon, S., Kitamei, H., Namba, K., Yoshida, K., Denhardt, D. T., Rittling, S. R., Ohno, S., Uede, T., Onoe, K.
(2007). Osteopontin Aggravates Experimental Autoimmune Uveoretinitis in Mice. J. Immunol.
178: 6567-6572
[Abstract][Full Text]
Juhn, P., Phillips, A., Buto, K.
(2007). Balancing Modern Medical Benefits And Risks. Health Aff (Millwood)
26: 647-652
[Abstract][Full Text]
Pizarro, T. T., Cominelli, F.
(2007). Cloning IL-1 and the Birth of a New Era in Cytokine Biology. J. Immunol.
178: 5411-5412
[Full Text]
Gonzalez-Rey, E., Chorny, A., Del Moral, R. G, Varela, N., Delgado, M.
(2007). Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann Rheum Dis
66: 582-588
[Abstract][Full Text]
Watson, A. J M
(2007). In vivo single-photon emission computed tomography imaging of apoptosis in Crohn's disease and anti-tumour necrosis factor therapy. Gut
56: 461-463
[Full Text]
Dorner, T., Burmester, G. R.
(2007). No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice. Rheumatology (Oxford)
46: 563-564
[Full Text]
Roos, J. C., Ostor, A. J., Okamoto, H., Dentener, M. A., Wouters, E. F.M., Scott, D.L., Kingsley, G.H.
(2006). Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis. NEJM
355: 2046-2048
[Full Text]